{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:57:55Z","timestamp":1785448675540,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravitreal anti\u2013vascular endothelial growth factor therapy is the first-line treatment for macular edema secondary to retinal vein occlusion. However, direct comparative evidence between ranibizumab and bevacizumab from randomized controlled trials remains limited. This study aimed to compare the efficacy and safety of these two agents using evidence from randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science from database inception to February 11, 2026. Eligible studies were published randomized controlled trials directly comparing intravitreal ranibizumab and bevacizumab monotherapy in adults with RVO-ME. Nonrandomized and noncomparative studies were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four randomized controlled trials involving 759 participants were included. At 6\u2009months, no significant difference was observed in mean best-corrected visual acuity (BCVA) change (MD 0.61 letters, 95% CI \u22121.95 to 3.18). The pooled mean difference in central macular thickness (CMT) change was 1.52\u2009\u03bcm (95% CI \u2212237.41 to 240.46). The proportion of eyes gaining\u2009\u2265\u200915 ETDRS letters was comparable (RR 0.97, 95% CI 0.82 to 1.14). Safety profiles were broadly similar. Rare systemic events were infrequent and associated with considerable statistical uncertainty. Certainty of evidence was moderate for visual outcomes and low to very low for rare adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ranibizumab and bevacizumab show comparable short-term efficacy and safety for macular edema secondary to retinal vein occlusion, although evidence for rare systemic events remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>PROSPERO CRD420251172336.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-05146-4","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:51:30Z","timestamp":1785401490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct randomized evidence comparing ranibizumab and bevacizumab for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yongfu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3265-4615","authenticated-orcid":false,"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"5146_CR1","doi-asserted-by":"publisher","unstructured":"I M, H A. Retinal vein occlusion review. Asia-Pac J Ophthalmol (Phila). 2017;7(1). https:\/\/doi.org\/10.22608\/APO.2017163442.","DOI":"10.22608\/APO.2017163442"},{"issue":"2","key":"5146_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313. https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.017.","journal-title":"Ophthalmology"},{"issue":"1","key":"5146_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-015-0005-8","volume":"1","author":"TE de Carlo","year":"2015","unstructured":"de Carlo TE, Romano A, Waheed NK, Duker JS. A review of optical coherence tomography angiography (OCTA). Int J Retin Vitr. 2015;1(1):5. https:\/\/doi.org\/10.1186\/s40942-015-0005-8.","journal-title":"Int J Retin Vitr"},{"issue":"1","key":"5146_CR4","doi-asserted-by":"publisher","first-page":"010427","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Global Health. 2019;9(1):010427. https:\/\/doi.org\/10.7189\/jogh.09.010427.","journal-title":"J Global Health"},{"issue":"3","key":"5146_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA). Ophthalmologica. 2019;242(3):123\u201362. https:\/\/doi.org\/10.1159\/000502041.","journal-title":"Ophthalmologica"},{"issue":"1","key":"5146_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4274\/tjo.galenos.2025.88262","volume":"55","author":"\u00d6 Candan","year":"2025","unstructured":"Candan \u00d6, Orman G, \u00dcnl\u00fc N, \u00dcney G, Burcu A. Prevalence of retinal vascular diseases in a tertiary care hospital in T\u00fcrkiye: a hospital-based epidemiologic study. Turk J Ophthalmol. 2025;55(1):16\u201323. https:\/\/doi.org\/10.4274\/tjo.galenos.2025.88262.","journal-title":"tjo"},{"issue":"1","key":"5146_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41433-026-04645-4","volume":"40","author":"C Dinah","year":"2026","unstructured":"Dinah C, et al. Response to: \u2018comment on: \u2018treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study\u201d. Eye. Nat Publishing Group. 2026;40(1):107\u201316. https:\/\/doi.org\/10.1038\/s41433-026-04645-4.","journal-title":"Eye. Nat Publishing Group"},{"issue":"5","key":"5146_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/00006982-200110000-00002","volume":"21","author":"EM Opremcak","year":"2001","unstructured":"Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina. 2001;21(5):408\u201315. https:\/\/doi.org\/10.1097\/00006982-200110000-00002.","journal-title":"Retina"},{"issue":"4","key":"5146_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.47102\/annals-acadmedsg.V36N4p293","volume":"36","author":"X-L Liang","year":"2007","unstructured":"Liang X-L, Chen H-Y, Huang Y-S, Au Eong K-GA, Liu X, Yan H, et al. Pars plana vitrectomy and internal limiting membrane peeling for macular oedema secondary to retinal vein occlusion: a pilot study. Ann Acad Med Singap. 2007;36(4):285\u201392. https:\/\/doi.org\/10.47102\/annals-acadmedsg.V36N4p293.","journal-title":"Ann Acad Med Singap"},{"issue":"1","key":"5146_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199901000-00001","volume":"19","author":"ME Opremcak","year":"1999","unstructured":"Opremcak ME, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina. 1999;19(1):1\u20135. https:\/\/doi.org\/10.1097\/00006982-199901000-00001.","journal-title":"Retina"},{"issue":"7","key":"5146_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00417-008-0830-7","volume":"246","author":"EJ Chung","year":"2008","unstructured":"Chung EJ, Lee H, Koh HJ. Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2008;246(7):967\u201374. https:\/\/doi.org\/10.1007\/s00417-008-0830-7.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"5146_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","volume":"98","author":"T Branch Vein Occlusion Study Group","year":"1984","unstructured":"Branch Vein Occlusion Study Group T. Argon laser photocoagulation for macular edema in branch vein occlusion. The branch vein occlusion study group. Am J Ophthalmol. 1984;98(3):271\u201382. https:\/\/doi.org\/10.1016\/0002-9394(84)90316-7.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"5146_CR13","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion. Ophthalmology. 2015;122(7):1426\u201337. https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.006.","journal-title":"Ophthalmology"},{"key":"5146_CR14","doi-asserted-by":"publisher","unstructured":"Frederiksen KH, Vestergaard JP, Pedersen FN, Vergmann AS, S\u00f8rensen TL, Laugesen CS, et al. Navigated laser and aflibercept versus aflibercept monotherapy in treatment-na\u00efve branch retinal vein occlusion: a 12-month randomized trial. Acta Ophthalmologica. 2022;100(7):e1503. https:\/\/doi.org\/10.1111\/aos.15182.","DOI":"10.1111\/aos.15182"},{"issue":"2","key":"5146_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/APO.0000000000000598","volume":"12","author":"F Romano","year":"2023","unstructured":"Romano F, Lamanna F, Gabrielle PH, Teo KYC, Battaglia Parodi M, Iacono P, et al. Update on retinal vein occlusion. Asia-Pac J Ophthalmol. 2023;12(2):196\u2013210. https:\/\/doi.org\/10.1097\/APO.0000000000000598.","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"5","key":"5146_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","volume":"36","author":"L Nicholson","year":"2022","unstructured":"Nicholson L, Talks SJ, Amoaku W, Talks K, Sivaprasad S. Retinal vein occlusion (RVO) guideline: executive summary. Eye. Nat Publishing Group. 2022;36(5):909\u201312. https:\/\/doi.org\/10.1038\/s41433-022-02007-4.","journal-title":"Eye. Nat Publishing Group"},{"issue":"6","key":"5146_CR17","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134\u201346.e3. https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.032.","journal-title":"Ophthalmology"},{"issue":"5","key":"5146_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.18240\/ijo.2025.05.13","volume":"18","author":"G Karata\u015f","year":"2025","unstructured":"Karata\u015f G, Uzundede T, Aday \u00d6, \u00d6zo\u011fuz AM, Karata\u015f ME, Kabakc\u0131 AK, et al. Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study. Int J Ophthalmol. 2025;18(5):876\u201382. https:\/\/doi.org\/10.18240\/ijo.2025.05.13.","journal-title":"Int J Ophthalmol"},{"key":"5146_CR19","doi-asserted-by":"publisher","unstructured":"Ramezani A, Esfandiari H, Entezari M, Moradian S, Soheilian M, Dehsarvi B, et al. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion. Acta Ophthalmologica. 2014;92(7):e530\u20139. https:\/\/doi.org\/10.1111\/aos.12317.","DOI":"10.1111\/aos.12317"},{"key":"5146_CR20","doi-asserted-by":"publisher","unstructured":"Hattenbach L-O, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N, et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmologica. 2018;96(1):e10\u20138. https:\/\/doi.org\/10.1111\/aos.13381.","DOI":"10.1111\/aos.13381"},{"issue":"1","key":"5146_CR21","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1038\/s41598-024-56581-6","volume":"14","author":"G Garay-Aramburu","year":"2024","unstructured":"Garay-Aramburu G, Hunt A, Arruabarrena C, Mehta H, Invernizzi A, Gabrielle P-H, et al. Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry. Sci Rep Nat Publishing Group. 2024;14(1):6122. https:\/\/doi.org\/10.1038\/s41598-024-56581-6.","journal-title":"Sci Rep Nat Publishing Group"},{"issue":"6","key":"5146_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.oret.2019.12.019","volume":"4","author":"MJC Vader","year":"2020","unstructured":"Vader MJC, Schauwvlieghe S, Verbraak FD, Dijkman G, Hooymans JMM, Los LI, et al. Comparing the efficacy of Bevacizumab and Ranibizumab in patients with retinal vein occlusion: the Bevacizumab to Ranibizumab in retinal vein occlusions (BRVO) study, a randomized trial. Ophthalmol Retina. 2020;4(6):576\u201387. https:\/\/doi.org\/10.1016\/j.oret.2019.12.019.","journal-title":"Ophthalmol Retina"},{"key":"5146_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2147\/OPTH.S163859","volume":"12","author":"JM Jumper","year":"2018","unstructured":"Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). OPTH. 2018;12:621\u201329. https:\/\/doi.org\/10.2147\/OPTH.S163859.","journal-title":"OPTH"},{"key":"5146_CR24","doi-asserted-by":"publisher","unstructured":"Yao J, Huang W, Gao L, Liu Y, Zhang Q, He J, et al. Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography: a network meta-analysis. PLoS ONE. Public Lib Sci. 2024;19(6):e0304283. https:\/\/doi.org\/10.1371\/journal.pone.0304283.","DOI":"10.1371\/journal.pone.0304283"},{"issue":"3","key":"5146_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ophtha.2016.10.036","volume":"124","author":"R Parikh","year":"2017","unstructured":"Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-vascular endothelial growth Factor use in ophthalmology among privately insured and Medicare advantage patients. Ophthalmology. 2017;124(3):352\u201358. https:\/\/doi.org\/10.1016\/j.ophtha.2016.10.036.","journal-title":"Ophthalmology"},{"issue":"5","key":"5146_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.4103\/IJO.IJO_2166_23","volume":"72","author":"S Singh","year":"2024","unstructured":"Singh S, Saxena S, Akduman L, Meyer CH. Off-label use of intravitreal bevacizumab: a global conundrum. Indian J Ophthalmol. 2024;72(5):617\u201319. https:\/\/doi.org\/10.4103\/IJO.IJO_2166_23.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"5146_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","volume":"134","author":"EL Ross","year":"2016","unstructured":"Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR, et al. Cost-effectiveness of aflibercept, Bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888\u201396. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.1669.","journal-title":"JAMA Ophthalmol"},{"key":"5146_CR28","doi-asserted-by":"publisher","unstructured":"van Asten F, Michels CTJ, Hoyng CB, van der Wilt GJ, Klevering BJ, Rovers MM, et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration\u2014A cost-effectiveness analysis from a societal perspective. PLoS ONE. 2018;13(5):e0197670. https:\/\/doi.org\/10.1371\/journal.pone.0197670.","DOI":"10.1371\/journal.pone.0197670"},{"key":"5146_CR29","doi-asserted-by":"publisher","unstructured":"Ford JA, Shyangdan D, Uthman OA, Lois N, Waugh N. Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis. BMJ Open. 2014;4(7):e005292. https:\/\/doi.org\/10.1136\/bmjopen-2014-005292.","DOI":"10.1136\/bmjopen-2014-005292"},{"key":"5146_CR30","doi-asserted-by":"publisher","unstructured":"Regnier SA, Larsen M, Bezlyak V, Allen F. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open. 2015;5(6):e007527. https:\/\/doi.org\/10.1136\/bmjopen-2014-007527.","DOI":"10.1136\/bmjopen-2014-007527"},{"issue":"9","key":"5146_CR31","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/17512433.2018.1507735","volume":"11","author":"S Sangroongruangsri","year":"2018","unstructured":"Sangroongruangsri S, Ratanapakorn T, Wu O, Anothaisintawee T, Chaikledkaew U. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2018;11(9):903\u201316. https:\/\/doi.org\/10.1080\/17512433.2018.1507735.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5146_CR32","doi-asserted-by":"publisher","unstructured":"Qian T, Zhao M, Wan Y, Li M, Xu X. Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion. BMJ Open. 2018;8(12):e022700. https:\/\/doi.org\/10.1136\/bmjopen-2018-022700.","DOI":"10.1136\/bmjopen-2018-022700"},{"key":"5146_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fphar.2021.752048","volume":"12","author":"S Gao","year":"2021","unstructured":"Gao S, Zhang Y, Li X, Ge G, Duan J, Lei C, et al. Comparative efficacy of pharmacotherapy for macular edema secondary to retinal vein occlusion: a network meta-analysis. Front Pharmacol. 2021;12:12. https:\/\/doi.org\/10.3389\/fphar.2021.752048.","journal-title":"Front Pharmacol"},{"issue":"6","key":"5146_CR34","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.survophthal.2025.05.008","volume":"70","author":"K-Y Chen","year":"2025","unstructured":"Chen K-Y, Chan H-C, Chan C-M. Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: a systematic review and network meta-analysis of randomized controlled trials. Surv Ophthalmol. 2025;70(6):1067\u201389. https:\/\/doi.org\/10.1016\/j.survophthal.2025.05.008.","journal-title":"Surv Ophthalmol"},{"key":"5146_CR35","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA, 2020 statement: an updated guideline for reporting systematic reviews. Br Med J Publishing Group. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"5146_CR36","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"issue":"3","key":"5146_CR37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1167\/iovs.08-2510","volume":"50","author":"M Funk","year":"2009","unstructured":"Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009;50(3):1025\u201332. https:\/\/doi.org\/10.1167\/iovs.08-2510.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"5146_CR38","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41433-022-02265-2","volume":"37","author":"S Arepalli","year":"2023","unstructured":"Arepalli S, Wykoff CC, Abraham JR, Lunasco L, Yu H, Hu M, et al. Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study. Eye (Lond). 2023;37(9):1928\u201335. https:\/\/doi.org\/10.1038\/s41433-022-02265-2.","journal-title":"Eye (Lond)"},{"issue":"10","key":"5146_CR39","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina Philadelphia, Pa. 2017;37(10):1847\u201358. https:\/\/doi.org\/10.1097\/IAE.0000000000001493.","journal-title":"Retina Philadelphia, Pa"},{"issue":"6","key":"5146_CR40","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmol Elsevier. 2010;117(6):1124\u201333.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2010.02.022.","journal-title":"Ophthalmol Elsevier"},{"key":"5146_CR41","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/DDDT.S67536","volume":"9","author":"X Sun","year":"2015","unstructured":"Sun X, Lu X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. DDDT. 2015;9:2311\u201320. https:\/\/doi.org\/10.2147\/DDDT.S67536.","journal-title":"DDDT"},{"key":"5146_CR42","unstructured":"Suresh B, Patel P. Aflibercept. In: StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 May 5]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK582136\/."},{"issue":"4","key":"5146_CR43","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik J-F, et al. Tenaya and Lucerne: rationale and design for the phase 3 clinical trials of Faricimab for neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1(4):100076. https:\/\/doi.org\/10.1016\/j.xops.2021.100076.","journal-title":"Ophthalmol Sci"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05146-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:02:36Z","timestamp":1785445356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05146-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5146"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05146-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a systematic review and meta-analysis of previously published research. Therefore, ethical approval and informed consent were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"449"}}